Showing results (1-10 of 26) with videos related to
Sort By:
Pageof 3
Asia-Pacific Journal of Clinical Oncology|June 24, 2020
Do histopathological features of breast cancer in Australian Indigenous women explain the survival disparity? A two decade long study in the Northern TerritoryDavid J Read, Sophia Frentzas, Linda Ward, et al.Cancer Reports (Hoboken, N.J.)|July 10, 2021
Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institutionSiddharth Menon, Amy Davies, Sophia Frentzas, et al.Cancer Immunology, Immunotherapy : CII|January 27, 2024
CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumorsJianghua Wang, Xiaoting Li, Guanxi Xiao, et al.Current Oncology (Toronto, Ont.)|August 28, 2024
Equitable Access to Genomic Molecular Testing for Australian Cancer Patients: Insights from the Victorian Precision Oncology SummitGenevieve Dall, Karen Harris, Nonie Chan, et al.Journal for Immunotherapy of Cancer|October 19, 2023
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumorsSophia Frentzas, Steven Kao, Rang Gao, et al.Nature Reviews. Clinical Oncology|April 7, 2011
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancerMartin D Forster, Konstantin J Dedes, Shahneen Sandhu, et al.JCO Global Oncology|September 19, 2025
Understanding Barriers to Clinical Cancer Research in the Asia-PacificRashid N Lui, Jimmy Billod, Sophia Frentzas, et al.Journal for Immunotherapy of Cancer|April 20, 2024
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumorsSophia Frentzas, Anna Rachelle Austria Mislang, Charlotte Lemech, et al.Oncology|October 12, 2011
Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trialsMontserrat Blanco Codesido, Andre Tesainer Brunetto, Sophia Frentzas, et al.NPJ Precision Oncology|December 7, 2023
Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibitionAsmerom T Sengal, Vanessa Bonazzi, Deborah Smith, et al.Pageof 3